About vinorelbin e
Vinca alkaloid chemotherapy medicine
Used for
- Treats non-small-cell lung cancer
- Treats advanced breast cancer
Usual adult dose
Usually given intravenously once weekly; dose is calculated by body surface area and adjusted for blood counts and treatment plan.
Common side effects
- Low white blood cell counts and infection risk
- Nausea, vomiting, constipation or diarrhoea
- Tiredness and hair loss
- Injection-site irritation or tissue damage if leakage occurs
Important warnings
- Can cause severe bone marrow suppression and infection.
- Must be given intravenously by trained staff; never administer into the spinal fluid.
- Liver problems may require dose adjustment.
- Avoid live vaccines during treatment; report fever promptly.
Pregnancy
May harm an unborn baby. Pregnancy should be avoided during treatment and for the period specified by the oncology team.
Breastfeeding
Breastfeeding is not recommended during treatment.
Interactions
- Other medicines that suppress bone marrow can increase blood-cell problems.
- Strong CYP3A inhibitors or inducers may alter vinorelbine levels.
- Mitomycin can increase the risk of lung toxicity.
- Live vaccines may cause serious infection during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.